期刊名称：DRUG DELIVERY AND TRANSLATIONAL RESEARCH
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
ISSN: 2190-393X (Print) 2190-3948 (Online)
- Accepted by ISI in SCIE, Biosis Previews and Biological Abstracts and will receive its first impact factor for 2015
- Drug Delivery and Translational Research is now indexed in PubMed!
- Explores the effect in different disease conditions of rationally developed, effective delivery systems
- Focuses on high-quality research on the development of novel drug delivery systems
- Presents full-length papers, communications, and reviews, editorials and more
Exclusively focused on translational aspects of drug delivery, this journal provides a unique forum for publication of high-quality research.
Drug Delivery and Translational Research publishes research focused on such topics as designing and developing novel drug delivery systems, with a focus on their application to disease conditions; preclinical and clinical data related to drug delivery systems; short-term and long-term biocompatibility of drug delivery systems, host response; biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering; image-guided drug therapy; nanomedicine; devices for drug delivery and drug/device combination products.
In addition to original full-length papers, communications, and reviews, the journal includes editorials, reports of future meetings, research highlights, and announcements pertaining to activities of the Controlled Release Society.
Drug Delivery and Translational Research publishes six issues a year.
Related subjects » Pharmacology & Toxicology
Abstracted/Indexed in
PubMed, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, OCLC, SCImago, Summon by ProQuest
Aims and Scope
The journal provides a unique forum for scientific publication of high-quality research that is exclusively focused on translational aspects of drug delivery. Rationally developed, effective delivery systems can potentially affect clinical outcome in different disease conditions.
Research focused on the following areas of translational drug delivery research will be considered for publication in the journal.
- Designing and developing novel drug delivery systems, with a focus on their application to disease conditions;
- Preclinical and clinical data related to drug delivery systems;
- Drug distribution, pharmacokinetics, clearance, with drug delivery systems as compared to traditional dosing to demonstrate beneficial outcomes
- Short-term and long-term biocompatibility of drug delivery systems, host response;
- Biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering;
- Image-guided drug therapy,
- Nanomedicine;
- Devices for drug delivery and drug/device combination products.
In addition to original full-length papers, communications, and reviews, the journal includes editorials, reports of future meetings, research highlights, and announcements pertaining to the activities of the Controlled Release Society.
Instructions to Authors
Manuscript Submission
Manuscript Submission
Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.
Permissions
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
Online Submission
Please follow the hyperlink “Submit online” on the right and upload all of your manuscript files following the instructions given on the screen.
Title page
Title Page
The title page should include:
- The name(s) of the author(s)
- A concise and informative title
- The affiliation(s) and address(es) of the author(s)
- The e-mail address, telephone and fax numbers of the corresponding author
Abstract
Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references.
Keywords
Please provide 4 to 6 keywords which can be used for indexing purposes.
Text
Text Formatting
Manuscripts should be submitted in Word.
- Use a normal, plain font (e.g., 10-point Times Roman) for text.
- Use italics for emphasis.
- Use the automatic page numbering function to number the pages.
- Do not use field functions.
- Use tab stops or other commands for indents, not the space bar.
- Use the table function, not spreadsheets, to make tables.
- Use the equation editor or MathType for equations.
- Save your file in docx format (Word 2007 or higher) or doc format (older Word versions).
Manuscripts with mathematical content can also be submitted in LaTeX.
Headings
Please use no more than three levels of displayed headings.
Abbreviations
Abbreviations should be defined at first mention and used consistently thereafter.
Footnotes
Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.
Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols.
Always use footnotes instead of endnotes.
Acknowledgments
Acknowledgments of people, grants, funds, etc. should be placed in a separate section on the title page. The names of funding organizations should be written in full.
Scientific style
Please always use internationally accepted signs and symbols for units (SI units).
Please use the standard mathematical notation for formulae, symbols etc.:
Italic for single letters that denote mathematical constants, variables, and unknown quantities
Roman/upright for numerals, operators, and punctuation, and commonly defined functions or abbreviations, e.g., cos, det, e or exp, lim, log, max, min, sin, tan, d (for derivative)
Bold for vectors, tensors, and matrices.
References
Citation
Reference citations in the text should be identified by numbers in square brackets. Some examples:
1. Negotiation research spans many disciplines [3].
2. This result was later contradicted by Becker and Seligman [5].
3. This effect has been widely studied [1-3, 7].
Reference list
The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a reference list.
The entries in the list should be numbered consecutively.
- Journal article
Smith JJ. The world of science. Am J Sci. 1999;36:234–5.
- Article by DOI
Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. J Mol Med. 2000; doi:10.1007/s001090000086
- Book
Blenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide to the management of common illness. 3rd ed. Oxford: Blackwell Science; 1998.
- Book chapter
Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. In: Bourne GH, Danielli JF, Jeon KW, editors. International review of cytology. London: Academic; 1980. pp. 251–306.
- Online document
Doe J. Title of subordinate document. In: The dictionary of substances and their effects. Royal Society of Chemistry. 1999. http://www.rsc.org/dose/title of subordinate document. Accessed 15 Jan 1999.
Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word Abbreviations, see
If you are unsure, please use the full journal title.
For authors using EndNote, Springer provides an output style that supports the formatting of in-text citations and reference list.
Tables
- All tables are to be numbered using Arabic numerals.
- Tables should always be cited in text in consecutive numerical order.
- For each table, please supply a table caption (title) explaining the components of the table.
- Identify any previously published material by giving the original source in the form of a reference at the end of the table caption.
- Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included beneath the table body.
Artwork and Illustrations Guidelines
Electronic Figure Submission
- Supply all figures electronically.
- Indicate what graphics program was used to create the artwork.
- For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MSOffice files are also acceptable.
- Vector graphics containing fonts must have the fonts embedded in the files.
- Name your figure files with "Fig" and the figure number, e.g., Fig1.eps.
Line Art
- Definition: Black and white graphic with no shading.
- Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at final size.
- All lines should be at least 0.1 mm (0.3 pt) wide.
- Scanned line drawings and line drawings in bitmap format should have a minimum resolution of 1200 dpi.
- Vector graphics containing fonts must have the fonts embedded in the files.
Halftone Art
- Definition: Photographs, drawings, or paintings with fine shading, etc.
- If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves.
- Halftones should have a minimum resolution of 300 dpi.
Combination Art
- Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive lettering, color diagrams, etc.
- Combination artwork should have a minimum resolution of 600 dpi.
Color Art
- Color art is free of charge for online publication.
- If black and white will be shown in the print version, make sure that the main information will still be visible. Many colors are not distinguishable from one another when converted to black and white. A simple way to check this is to make a xerographic copy to see if the necessary distinctions between the different colors are still apparent.
- If the figures will be printed in black and white, do not refer to color in the captions.
- Color illustrations should be submitted as RGB (8 bits per channel).
Figure Lettering
- To add lettering, it is best to use Helvetica or Arial (sans serif fonts).
- Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–12 pt).
- Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an axis and 20-pt type for the axis label.
- Avoid effects such as shading, outline letters, etc.
- Do not include titles or captions within your illustrations.
Figure Numbering
- All figures are to be numbered using Arabic numerals.
- Figures should always be cited in text in consecutive numerical order.
- Figure parts should be denoted by lowercase letters (a, b, c, etc.).
- If an appendix appears in your article and it contains one or more figures, continue the consecutive numbering of the main text. Do not number the appendix figures,
"A1, A2, A3, etc." Figures in online appendices (Electronic Supplementary Material) should, however, be numbered separately.
Figure Captions
- Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.
- Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.
- No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
- Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
- Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.
Figure Placement and Size
- Figures should be submitted separately from the text, if possible.
- When preparing your figures, size figures to fit in the column width.
- For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not higher than 234 mm.
- For books and book-sized journals, the figures should be 80 mm or 122 mm wide and not higher than 198 mm.
Permissions
If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.
Accessibility
In order to give people of all abilities and disabilities access to the content of your figures, please make sure that
- All figures have descriptive captions (blind users could then use a text-to-speech software or a text-to-Braille hardware)
- Patterns are used instead of or in addition to colors for conveying information (colorblind users would then be able to distinguish the visual elements)
- Any figure lettering has a contrast ratio of at least 4.5:1
Electronic Supplementary Material
Integrity of research and reporting
Ethical standards
Manuscripts submitted for publication must contain a declaration that the experiments comply with the current laws of the country in which they were performed. Please include this note in a separate section before the reference list.
Conflict of interest Disclosure
When authors submit a manuscript, they are responsible for disclosing all financial and personal relationships that might bias their work. To prevent ambiguity, authors must state explicitly whether potential conflicts do or do not exist. Each author must indicate whether or not they have a financial relationship with the organization that sponsored the research. For each source of funds, both the research funder and the grant number should be given.
Potential conflicts of interest exist when an author is related to a for-profit company or institution in any of the following ways:
1. Employment
2. Consultancies in the last 3 years (please list)
3. Honoraria in the last 3 years (please list)
4. Stock ownership/ options other than mutual funds (current; please list)
5. Expert testimony in the last 3 years (please list)
6. Grants received in the last 3 years (please list)
7. Grants pending (please list)
8. Patents received
9. Patents pending
10. Royalties (describe)
11. Other relationships (please specify)
Conflict of interest statements should be present on every manuscript before the References section. The statement should mention each author separately by name.
Recommended wording is as follows:
Author X declares that he has no conflict of interest.
Author Y has received research grants from Drug Company A.
Author Z has received a speaker honorarium from Drug Company B and owns stock in Drug Company C.
If multiple authors declare no conflict, this can be done in one sentence:
Author X, Author Y and Author Z declare that they have no conflict of interest.
Follow the below link for Springer's Conflict of Interest Statement:
The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or failure to fulfill the above-mentioned requirements
Follow the below link for Springer's Animal and Human Rights Statement
Informed Consent
For studies with human subjects, please include the following statement before the References section:
'All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.'
Any experimental protocol must be approved, and owing to US regulations (the recent Health Insurance Portability and Accountability Act - HIPAA) even studies without any experimental protocol merely reporting patients or patient material require approval; these regulations require review for any studies involving patient identity, including retrospective chart, radiographic reviews, or removed tissues or materials.
If any identifying information about patients is included in the article, the following sentence should also be included:
'Additional informed consent was obtained from all patients for which identifying information is included in this article.'
Follow the below link for Springer's Informed Consent Statement:
Animal Studies
For studies with animals, include the following sentence in the manuscript before the References section:
'All institutional and national guidelines for the care and use of laboratory animals were followed.'
If the authors did not carry out animal and/or human studies as part of their article they must include the following statement in the manuscript before the References section:
'No animal or human studies were carried out by the authors for this article'
After acceptance
Upon acceptance of your article you will receive a link to the special Author Query Application at Springer’s web page where you can sign the Copyright Transfer Statement online and indicate whether you wish to order OpenChoice, offprints, or printing of figures in color.
Once the Author Query Application has been completed, your article will be processed and you will receive the proofs.
Open Choice
In addition to the normal publication process (whereby an article is submitted to the journal and access to that article is granted to customers who have purchased a subscription), Springer provides an alternative publishing option: Springer Open Choice. A Springer Open Choice article receives all the benefits of a regular subscription-based article, but in addition is made available publicly through Springer’s online platform SpringerLink.
Copyright transfer
Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive publication and dissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws.
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution License.
Offprints
Offprints can be ordered by the corresponding author.
Color illustrations
Online publication of color illustrations is free of charge. For color in the print version, authors will be expected to make a contribution towards the extra costs.
Proof reading
The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor.
After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article.
Online First
The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers.
Does Springer provide English language support?
Manuscripts that are accepted for publication will be checked by our copyeditors for spelling and formal style. This may not be sufficient if English is not your native language and substantial editing would be required. In that case, you may want to have your manuscript edited by a native speaker prior to submission. A clear and concise language will help editors and reviewers concentrate on the scientific content of your paper and thus smooth the peer review process.
The following editing service provides language editing for scientific articles in all areas Springer
publishes in:
Use of an editing service is neither a requirement nor a guarantee of acceptance for publication.
Please contact the editing service directly to make arrangements for editing and payment.
For Authors from China
文章在投稿前进行专业的语言润色将对作者的投稿进程有所帮助。作者可自愿选择使用Springer推荐的编辑服务，使用与否并不作为判断文章是否被录用的依据。提高文章的语言质量将有助于审稿人理解文章的内容，通过对学术内容的判断来决定文章的取舍，而不会因为语言问题导致直接退稿。作者需自行联系 Springer推荐的编辑服务公司，协商编辑事宜。
For Authors from Japan
ジャーナルに論文を投稿する前に、ネイティブ・スピーカーによる英文校閲を希望されている方には、Edanz社をご紹介しています。サービス内容、料金および申込方法など、日本語による詳しい説明はエダンズグループジャパン株式会社の下記サイトをご覧ください。
For Authors from Korea
영어 논문 투고에 앞서 원어민에게 영문 교정을 받고자 하시는 분들께 Edanz 회사를 소개해 드립니다. 서비스 내용, 가격 및
신청 방법 등에 대한 자세한 사항은 저희 Edanz Editing Global 웹사이트를 참조해 주시면 감사하겠습니다.
Additional Information
Drug Delivery and Translational Research is a multidisciplinary journal that is indispensable to those whose research focus is on the science and technology of delivering bioactives that have potential implications for a range of disease conditions.
Research Articles
Reports of original research on the science and technology of delivery of bioactives, especially studies with a translational focus, are encouraged. Research involving new concepts in drug delivery with potential implications in various disease conditions and regenerative medicine are preferred for this journal.
Articles involving routine drug delivery formulation study and/or optimization of parameters without documented data on their efficacy are discouraged.
Reviews
Reviews considered for publication in this journal are written on current topics relevant to drug delivery and translational research, providing critical analysis of the subject area and its overall impact on health care. Reviews typically should be 6-10 printed pages, including figures and references.
Reviews containing only a survey of the recent literature are discouraged.
Short communications
Short communications should report recent findings of high impact and should include a brief abstract and a combined narrative description of experimental methods, results and discussion, as well as significance of the findings. Short communications typically comprise 2-3 printed pages, including figures and references.
Research Highlights
Drug delivery research with high and global impact on disease treatment, control, and prevention or difficult to treat and rare diseases may be considered for publication as “Research Highlights”.
Methods
Articles describing new device designs and methods of delivery of bioactives with significant potential benefits over conventional methods of delivery are encouraged.
Editorial Board
Editor-in-Chief:
Vinod Labhasetwar, Cleveland Clinic, Cleveland, OH, USA
Associate Editors:
Ben J. Boyd, Monash Institute of Pharmaceutical Sciences, Victoria, Australia
Martyn Davies, University of Nottingham, Nottingham, UK
Justin Hanes, The Johns Hopkins University, Baltimore, MD, USA
Editorial Board:
Rinti Banerjee, Indian Institute of Technology, Bombay, Mumbai, India
Raymond Bartus, Ceregene Inc., San Diego, CA, USA
Jayesh Bellare, Indian Institute of Technology, Bombay, Mumbai, India
Diane Burgess, University of Connecticut, Storrs, CT, USA
Perry Calias, Shire HGT, Lexington, MA, USA
Sing Yian Chew, Nanyang Technological University, Singapore, Singapore
Mark Davis, California Institute of Technology, Pasadena, CA, USA
Kenneth Dawson, University College Dublin, Dublin, Ireland
Michael R. Doschak, University of Alberta, Edmonton, Alberta, Canada
Elazer Edelman, Massachusetts Institute of Technology, Cambridge, MA, USA
Pierandrea Esposito, SiTec Consulting, Barcelona, Spain
David Friend, CONRAD, Arlington, VA, USA
Rogerio Gaspar, University of Lisboa, Lisboa, Portugal
Kenneth Howard, Aarhus University, Aarhus, Denmark
Jeffrey Hubbell, Institute of Bioengineering, EPFL, Lausanne, Switzerland
Lisbeth Illum, IDentity, Nottingham, UK
Mansoor Khan, Food and Drug Administration, Silver Spring, MD, USA
Robert Levy, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
Weiyue Lu, Fudan University, Shanghai, China
David Lynn, University of Wisconsin, Madison, WI, USA
Natalie Medlicott, University of Otago, Dunedin, New Zealand
Tamara Minko, Rutgers University, Piscataway, NJ, USA
Samir Mitragotri, University of California, Santa Barbara, CA, USA
Kinam Park, Purdue University, West Lafayette, IN, USA (Honorary Member)
Mark Prausnitz, Georgia Institute of Technology, Atlanta, GA, USA
Suzie Pun, University of Washington, Seattle, WA, USA
Michael Rathbone, International Medical University, Kuala Lumpur, Malaysia
Lonnie Shea, University of Michigan, Ann Arbor, MI, USA
Patrick Sinko, Rutgers University, Piscataway, NJ, USA
V. Prasad Shastri, University of Freiburg, Freiburg, Germany
Thomas Tice, Evonik Degussa Corporation, Birmingham, AL, USA
Elka Touitou, Hebrew University of Jerusalem, Jerusalem, Israel
Ijeoma Uchegbu, University of London, London, UK
Xiao Yu (Shirley) Wu, University of Toronto, Toronto, ON, Canada
Qiang Zhang, Peking University, Beijing, China
|
